培训课件--优化COPD管理.pptVIP

* * * 布地奈德/福莫特罗was superior to 安慰剂, 布地奈德 and 福莫特罗 regarding morning PEF in both the Szafranski and Calverley studies. As can be seen from the graph above from the Szafranski study, no apparent decline in PEF was seen over the 12-month period, thus not showing any signs of tolerance development. The changes presented here are for pre-dose values, as compared to post-dose values for FEV1 measurements. PEF improvements in the Szafranski study reflect improvements from a baseline with rescue medication only during the conventional run-in period. * Date of preparation Sept 2007. Prescri